MDR1 gene expression in primary and advanced breast cancer

Laboratory Investigation

Volumn 79, Issue 3, 1999, Pages 271-280

  Yang, Xiaowei ^a,b   Uziely, Beatrice ^a,c   Groshen, Susan ^a,b   Lukas, Jason ^a,b   Israel, Valerie ^a,b   Russell, Christy ^a,b   Dunnington, Gary ^b   Formenti, Silvia ^a,b   Muggia, Franco ^a,b   Press, Michael F ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0032919439     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, and Weinstein R (1996). Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 56:3010-3020.
2. Biedler JL and Riehn H (1970). Cellular resistance to actinomycin D in Chinese hamster ovary cells in vitro: Cross resistance, radiographic, and cytogenetic studies. Cancer Res 30:1174-1184.
3. Bradley G, Naik M, and Ling V (1989). P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 49:2790-2796.
4. Brophy N, Marie J, Rojas V, Warnke R, McFall P, Smith S, and Sikic B (1994). Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques. Leukemia 8:327-335.
5. Chan HSL and Ling V (1997). Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: Diagnostic and clinical implications. J Natl Cancer Inst 89:1473-1476.
6. Chan H, Thorner P, Haddad G, and Ling V (1990). Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704.
7. Chan H, Haddad G, Thorner P, DeBoer G, Lin Y, Ondrusek N, Yeger H, and Ling V (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614.
8. Chaudhary PM, Mechetner EB, and Roninson IB (1992). Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 11:2735-2739.
9. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
10. De La Torre M, Larsson R, Nygren P, Lindgren A, and Bergh J (1994). Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers. Acta Oncol 33:773-777.
11. Dixon AR, Bell J, Ellis IO, Elston CW, and Blarney RW (1992). P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. Br J Cancer 66:537-541.
12. Drach D, Shourong Z, Drach J, Mahaderia R, Gattringer C, Huber H, and Andreeff M (1992). Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734.
13. Endicott J and Ling V (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
14. Filipits M, Suchomel R, Dekan G, Haider K, Valdimarsson G, Depisch D, and Pirker R (1996). MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2:1231-1237.
15. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987). Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:256-269.
16. Goldie JH and Goldman AJ (1985). Genetic instability in the development of drug resistance. Semin Oncol 12:222-230.
17. Gregorcyk S, Kang Y, Brandt D, Kolm P, Singer G, and Perry R (1996). P-glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 3:8-14.
18. Gussow D, Rein R, Ginjaar E, Hochstenbach F, Seemann G, Kottman A, and Plough FL (1987). The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 139:3132-3138.
19. He L, Hao C, Lin B, Wang Y, and Gao F (1995). P-glycoprotein expression in primary breast cancer. Clin Med Sci J 10:12-15.
20. Hegewisch-Becker S, Staib F, Loning T, Pichlmeier U, Kroger N, Reymann A, and Hossfeld D (1998). No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Ann Oncol 9:85-93.
21. Kane SE, Pastan I, and Gottesman MM (1990). Genetic basis of multidrug resistance of tumor cells. Bioenerg Biomembr 22:593-618.
22. Kartner N, Riordan JR, and Ling V (1983). Cell surface P-glycoprotein is associated with multidrug resistance in mammalian cell line. Science 221:1285-1288.
23. Klimecki WT, Futscher BW, Grogan TM, and Dalton WS (1994). P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458.
24. Leith C, Chen I, Kopecky K, Appelbaum F, Head D, Godwin J, Weick J, and Willman C (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye/ drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR+/efflux- cases. Blood 86:2329-2342.
25. Ling V, Kartner N, Sudo T, Siminovitch L, and Riordan JR (1983). Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67:869-874.
26. Liu B, Sun D, Xia W, Hung M-C, and Yu D (1997). Cross-reactivity of C219 anti-p170 mdr1 antibody with p185 c-erb2 in breast cancer cells: cautions on evaluating p170 mdr-1. J Natl Cancer Inst 89:1524-1529.
27. Loflin P and Zwelling L (1994). Topoisomerase II and the path of apoptosis. Contemp Oncol 11:46-57.
28. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D, Housman D, and Jacks T (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
29. Maas R, Bruning P, Breedijk AJ, Top B, and Peterse HL (1995). Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. Lab Invest 72: 760-764.
30. Marie J, Zittoun R, and Sikic B (1991). Multidrug resistance (MDR1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592.
31. Merkel DE, Fuqua AW, Tandon AK, Hill SM, Buzdar AU, and McGuire WL (1989). Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein expression or gene amplification. J Clin Oncol 7:1129-1136.
32. Muss H, Thor AD, Berry D, Kute T, Liu E, Koerner F, Cirrincione C, Budman D, Wood W, Barcos M, and Henderson I (1994). Cerb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266.
33. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, and Roninson IB (1990). Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164.
34. Pirker R, Wallner J, Geissler K, Linkesch W, Haas O, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, and Lechner K (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712.
35. Press MF and Greene GL (1984). An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest 50:480-486.
36. Press MF, Nousek-Goebl NA, and Greene GL (1985). Immunoelectron microscopic localization of estrogen receptor with monoclonal antibodies. J Histochem Cytochem 33:915-924.
37. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, and Blick M (1990). Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787-791.
38. Roninson IB, Abelson HT, Husman DE, Howell N, and Varshavsky A (1984). Amplification of specific DNA sequences correlates with multidrug resistance in Chinese hamster cells. Nature 309:626-628.
39. Sanfillippo O, Ronchi E, DeMarco C, Di-Fronzo G, and Silvestrini R (1991). Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27:155-158.
40. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, and Volm M (1989). P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60:815-818.
41. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, and Mori S (1988). Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK-16. Cancer Res 48:1926-1929.
42. Tannock IF (1987). Experimental chemotherapy. In: Tannock IF and Hill RP, editors. The basic science of oncology. New York: McGraw-Hill, Inc., 308-325.
43. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willmgham MC (1989). Immunohistochemical localisation in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localisation in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159-164.
44. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, and Gazdar AF (1993). Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. 85:897-901.
45. Veneroni S, Zaffaroni N, Daidone M, Benini E, Villa R, and Silvestrini R (1994). Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A:1002-1007.
46. Woodhouse J and Ferry D (1995). The genetic basis of resistance to cancer chemotherapy. Ann Med 27:157-167.
47. Yang X and Page M (1995). An Mr 7-kDa membrane protein overexpressed in human multidrug-resistant ovarian cancer cells. Cancer Lett 88:171-178.
48. Yang X and Page M (1996). Growth regulation of multidrug resistant ovarian cancer cells by 1D7 monoclonal antibody. Anticancer Res 16:273-276.